Sept. 18, 2017 Price forecast | 2 weeks: 4.44% | 1 month: 5.21% | 3 months: 3.87%


NBRV stock forecast

Our latest prediction for Nabriva Therapeutics Plc's stock price was made on the Sept. 18, 2017 when the stock price was at 8.87$.

In the short term (2weeks), NBRV's stock price should outperform the market by 4.44%. During that period the price should oscillate between -9.55% and +14.05%.

In the medium term (3months), NBRV's stock price should outperform the market by 3.87%. During that period the price should oscillate between -19.09% and +32.00%.


About Nabriva Therapeutics Plc

Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

At the moment the company generates 1M USD in revenues.

On its last earning announcement, the company reported a loss of -2.04$ per share.

The book value per share is 1.12$

Nabriva Therapeutics Plc website


Three months stock forecastSept. 18, 2017


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
1M - -124M - -126M -2.04 - - 67M 1.12 -81M - -81M